845 related articles for article (PubMed ID: 34588751)
21. Microbial dysbiosis-induced obesity: role of gut microbiota in homoeostasis of energy metabolism.
Amabebe E; Robert FO; Agbalalah T; Orubu ESF
Br J Nutr; 2020 May; 123(10):1127-1137. PubMed ID: 32008579
[TBL] [Abstract][Full Text] [Related]
22. Citrus flavonoids and the intestinal barrier: Interactions and effects.
Wang M; Zhao H; Wen X; Ho CT; Li S
Compr Rev Food Sci Food Saf; 2021 Jan; 20(1):225-251. PubMed ID: 33443802
[TBL] [Abstract][Full Text] [Related]
23. Gut microbiota-derived metabolites in obesity: a systematic review.
Ejtahed HS; Angoorani P; Soroush AR; Hasani-Ranjbar S; Siadat SD; Larijani B
Biosci Microbiota Food Health; 2020; 39(3):65-76. PubMed ID: 32775123
[TBL] [Abstract][Full Text] [Related]
24. Molecular Paths Linking Metabolic Diseases, Gut Microbiota Dysbiosis and Enterobacteria Infections.
Serino M
J Mol Biol; 2018 Mar; 430(5):581-590. PubMed ID: 29374557
[TBL] [Abstract][Full Text] [Related]
25. Gut Microbiota and Obesity: A Role for Probiotics.
Abenavoli L; Scarpellini E; Colica C; Boccuto L; Salehi B; Sharifi-Rad J; Aiello V; Romano B; De Lorenzo A; Izzo AA; Capasso R
Nutrients; 2019 Nov; 11(11):. PubMed ID: 31703257
[TBL] [Abstract][Full Text] [Related]
26. Impact of the Gut Microbiota on Intestinal Immunity Mediated by Tryptophan Metabolism.
Gao J; Xu K; Liu H; Liu G; Bai M; Peng C; Li T; Yin Y
Front Cell Infect Microbiol; 2018; 8():13. PubMed ID: 29468141
[TBL] [Abstract][Full Text] [Related]
27. The metabolic and vascular protective effects of olive (Olea europaea L.) leaf extract in diet-induced obesity in mice are related to the amelioration of gut microbiota dysbiosis and to its immunomodulatory properties.
Vezza T; Rodríguez-Nogales A; Algieri F; Garrido-Mesa J; Romero M; Sánchez M; Toral M; Martín-García B; Gómez-Caravaca AM; Arráez-Román D; Segura-Carretero A; Micol V; García F; Utrilla MP; Duarte J; Rodríguez-Cabezas ME; Gálvez J
Pharmacol Res; 2019 Dec; 150():104487. PubMed ID: 31610229
[TBL] [Abstract][Full Text] [Related]
28. Disruptions in gut microbial-host co-metabolism and the development of metabolic disorders.
Rajani C; Jia W
Clin Sci (Lond); 2018 Apr; 132(7):791-811. PubMed ID: 29661926
[TBL] [Abstract][Full Text] [Related]
29. The intestinal microbiota fuelling metabolic inflammation.
Tilg H; Zmora N; Adolph TE; Elinav E
Nat Rev Immunol; 2020 Jan; 20(1):40-54. PubMed ID: 31388093
[TBL] [Abstract][Full Text] [Related]
30. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
[TBL] [Abstract][Full Text] [Related]
31. The Role of Microbiota on the Gut Immunology.
Min YW; Rhee PL
Clin Ther; 2015 May; 37(5):968-75. PubMed ID: 25846321
[TBL] [Abstract][Full Text] [Related]
32. Our Little Friends with Big Roles: Alterations of the Gut Microbiota in Thyroid Disorders.
Ejtahed HS; Angoorani P; Soroush AR; Siadat SD; Shirzad N; Hasani-Ranjbar S; Larijani B
Endocr Metab Immune Disord Drug Targets; 2020; 20(3):344-350. PubMed ID: 31566142
[TBL] [Abstract][Full Text] [Related]
33. Gut barrier disruption and chronic disease.
Martel J; Chang SH; Ko YF; Hwang TL; Young JD; Ojcius DM
Trends Endocrinol Metab; 2022 Apr; 33(4):247-265. PubMed ID: 35151560
[TBL] [Abstract][Full Text] [Related]
34. Gut microbiota in ulcerative colitis: insights on pathogenesis and treatment.
Guo XY; Liu XJ; Hao JY
J Dig Dis; 2020 Mar; 21(3):147-159. PubMed ID: 32040250
[TBL] [Abstract][Full Text] [Related]
35. Crossing the barriers: Revisiting the gut feeling in rheumatoid arthritis.
Brandl C; Bucci L; Schett G; Zaiss MM
Eur J Immunol; 2021 Apr; 51(4):798-810. PubMed ID: 33594693
[TBL] [Abstract][Full Text] [Related]
36. Metabolism at the centre of the host-microbe relationship.
Maslowski KM
Clin Exp Immunol; 2019 Aug; 197(2):193-204. PubMed ID: 31107965
[TBL] [Abstract][Full Text] [Related]
37. Microbiota-Immune System Interactions in Human Neurological Disorders.
Huang Q; Yu F; Liao D; Xia J
CNS Neurol Disord Drug Targets; 2020; 19(7):509-526. PubMed ID: 32713337
[TBL] [Abstract][Full Text] [Related]
38. Intestinal Barrier in Human Health and Disease.
Di Tommaso N; Gasbarrini A; Ponziani FR
Int J Environ Res Public Health; 2021 Dec; 18(23):. PubMed ID: 34886561
[TBL] [Abstract][Full Text] [Related]
39. Gut microbiome, endocrine control of gut barrier function and metabolic diseases.
Régnier M; Van Hul M; Knauf C; Cani PD
J Endocrinol; 2021 Feb; 248(2):R67-R82. PubMed ID: 33295880
[TBL] [Abstract][Full Text] [Related]
40. The Emerging Role of Gut Dysbiosis in Cardio-metabolic Risk Factors for Heart Failure.
Sata Y; Marques FZ; Kaye DM
Curr Hypertens Rep; 2020 May; 22(5):38. PubMed ID: 32385705
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
